On the other hand, low serum survivin levels have been shown to be associated with a slightly better response in patients with pancreatic cancer.[53] These findings may increase our understanding of the different functions of the survivin protein.[54–56] We found that only the baseline serum survivin level was associated with the therapeutic response among the clinicopathological features. This evidence concerns the gene BIRC5 and familial pancreatic carcinoma.